137 related articles for article (PubMed ID: 22070409)
1. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 attenuates a scopolamine-induced deficit in a novel rodent attention task.
Vardigan JD; Converso A; Hutson PH; Uslaner JM
J Neurogenet; 2011 Dec; 25(4):120-6. PubMed ID: 22070409
[TBL] [Abstract][Full Text] [Related]
2. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents.
Hutson PH; Finger EN; Magliaro BC; Smith SM; Converso A; Sanderson PE; Mullins D; Hyde LA; Eschle BK; Turnbull Z; Sloan H; Guzzi M; Zhang X; Wang A; Rindgen D; Mazzola R; Vivian JA; Eddins D; Uslaner JM; Bednar R; Gambone C; Le-Mair W; Marino MJ; Sachs N; Xu G; Parmentier-Batteur S
Neuropharmacology; 2011 Sep; 61(4):665-76. PubMed ID: 21619887
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel PDE9 inhibitors capable of inhibiting Aβ aggregation as potential candidates for the treatment of Alzheimer's disease.
Su T; Zhang T; Xie S; Yan J; Wu Y; Li X; Huang L; Luo HB
Sci Rep; 2016 Feb; 6():21826. PubMed ID: 26911795
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of acetylcholinesterase and phosphodiesterase-9A has differential effects on hippocampal early and late LTP.
Kroker KS; Rast G; Giovannini R; Marti A; Dorner-Ciossek C; Rosenbrock H
Neuropharmacology; 2012 Apr; 62(5-6):1964-74. PubMed ID: 22245562
[TBL] [Abstract][Full Text] [Related]
5. PDE9A inhibition rescues amyloid beta-induced deficits in synaptic plasticity and cognition.
Kroker KS; Mathis C; Marti A; Cassel JC; Rosenbrock H; Dorner-Ciossek C
Neurobiol Aging; 2014 Sep; 35(9):2072-8. PubMed ID: 24746365
[TBL] [Abstract][Full Text] [Related]
6. The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents.
van der Staay FJ; Rutten K; Bärfacker L; Devry J; Erb C; Heckroth H; Karthaus D; Tersteegen A; van Kampen M; Blokland A; Prickaerts J; Reymann KG; Schröder UH; Hendrix M
Neuropharmacology; 2008 Oct; 55(5):908-18. PubMed ID: 18674549
[TBL] [Abstract][Full Text] [Related]
7. Two novel 5-HT6 receptor antagonists ameliorate scopolamine-induced memory deficits in the object recognition and object location tasks in Wistar rats.
de Bruin NM; Prickaerts J; van Loevezijn A; Venhorst J; de Groote L; Houba P; Reneerkens O; Akkerman S; Kruse CG
Neurobiol Learn Mem; 2011 Sep; 96(2):392-402. PubMed ID: 21757018
[TBL] [Abstract][Full Text] [Related]
8. Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders.
Verhoest PR; Fonseca KR; Hou X; Proulx-Lafrance C; Corman M; Helal CJ; Claffey MM; Tuttle JB; Coffman KJ; Liu S; Nelson F; Kleiman RJ; Menniti FS; Schmidt CJ; Vanase-Frawley M; Liras S
J Med Chem; 2012 Nov; 55(21):9045-54. PubMed ID: 22780914
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line.
Wunder F; Tersteegen A; Rebmann A; Erb C; Fahrig T; Hendrix M
Mol Pharmacol; 2005 Dec; 68(6):1775-81. PubMed ID: 16150925
[TBL] [Abstract][Full Text] [Related]
10. Hemodynamic, Hormonal, and Renal Actions of Phosphodiesterase-9 Inhibition in Experimental Heart Failure.
Scott NJA; Rademaker MT; Charles CJ; Espiner EA; Richards AM
J Am Coll Cardiol; 2019 Aug; 74(7):889-901. PubMed ID: 31416533
[TBL] [Abstract][Full Text] [Related]
11. The Novel Phosphodiesterase 9A Inhibitor BI 409306 Increases Cyclic Guanosine Monophosphate Levels in the Brain, Promotes Synaptic Plasticity, and Enhances Memory Function in Rodents.
Rosenbrock H; Giovannini R; Schänzle G; Koros E; Runge F; Fuchs H; Marti A; Reymann KG; Schröder UH; Fedele E; Dorner-Ciossek C
J Pharmacol Exp Ther; 2019 Dec; 371(3):633-641. PubMed ID: 31578258
[No Abstract] [Full Text] [Related]
12. Discovery of a phosphodiesterase 9A inhibitor as a potential hypoglycemic agent.
Shao YX; Huang M; Cui W; Feng LJ; Wu Y; Cai Y; Li Z; Zhu X; Liu P; Wan Y; Ke H; Luo HB
J Med Chem; 2014 Dec; 57(24):10304-13. PubMed ID: 25432025
[TBL] [Abstract][Full Text] [Related]
13. Role of PDE9 in Cognition.
Dorner-Ciossek C; Kroker KS; Rosenbrock H
Adv Neurobiol; 2017; 17():231-254. PubMed ID: 28956335
[TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase type 5 (PDE5) inhibition improves object recognition memory: indications for central and peripheral mechanisms.
Reneerkens OA; Rutten K; Akkerman S; Blokland A; Shaffer CL; Menniti FS; Steinbusch HW; Prickaerts J
Neurobiol Learn Mem; 2012 May; 97(4):370-9. PubMed ID: 22426465
[TBL] [Abstract][Full Text] [Related]
15. Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo.
Kleiman RJ; Chapin DS; Christoffersen C; Freeman J; Fonseca KR; Geoghegan KF; Grimwood S; Guanowsky V; Hajós M; Harms JF; Helal CJ; Hoffmann WE; Kocan GP; Majchrzak MJ; McGinnis D; McLean S; Menniti FS; Nelson F; Roof R; Schmidt AW; Seymour PA; Stephenson DT; Tingley FD; Vanase-Frawley M; Verhoest PR; Schmidt CJ
J Pharmacol Exp Ther; 2012 May; 341(2):396-409. PubMed ID: 22328573
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and evaluation of pyrazolopyrimidinone derivatives as novel PDE9A inhibitors for treatment of Alzheimer's disease.
Zhang P; Jiang MY; Le ML; Zhang B; Zhou Q; Wu Y; Zhang C; Luo HB
Bioorg Med Chem Lett; 2020 Jul; 30(14):127254. PubMed ID: 32527553
[TBL] [Abstract][Full Text] [Related]
17. CRD-733, a Novel PDE9 (Phosphodiesterase 9) Inhibitor, Reverses Pressure Overload-Induced Heart Failure.
Richards DA; Aronovitz MJ; Liu P; Martin GL; Tam K; Pande S; Karas RH; Bloomfield DM; Mendelsohn ME; Blanton RM
Circ Heart Fail; 2021 Jan; 14(1):e007300. PubMed ID: 33464954
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Potent, Selective, and Orally Bioavailable Inhibitors against Phosphodiesterase-9, a Novel Target for the Treatment of Vascular Dementia.
Wu Y; Zhou Q; Zhang T; Li Z; Chen YP; Zhang P; Yu YF; Geng H; Tian YJ; Zhang C; Wang Y; Chen JW; Chen Y; Luo HB
J Med Chem; 2019 Apr; 62(8):4218-4224. PubMed ID: 30916555
[TBL] [Abstract][Full Text] [Related]
19. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey.
Smith SM; Uslaner JM; Cox CD; Huszar SL; Cannon CE; Vardigan JD; Eddins D; Toolan DM; Kandebo M; Yao L; Raheem IT; Schreier JD; Breslin MJ; Coleman PJ; Renger JJ
Neuropharmacology; 2013 Jan; 64():215-23. PubMed ID: 22750078
[TBL] [Abstract][Full Text] [Related]
20. PDE9 inhibition promotes proliferation of neural stem cells via cGMP-PKG pathway following oxygen-glucose deprivation/reoxygenation injury in vitro.
Huan X; Oumei C; Hongmei Q; Junxia Y; Xiaojiao M; Qingsong J
Neurochem Int; 2020 Feb; 133():104630. PubMed ID: 31821840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
